Navigation Links
Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

- DDP733 reduces esophageal reflux -

Waltham, Mass., June 7, 2007 – Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-of-concept for DDP733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achieved statistical significance over placebo on the primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen is planning to initiate a Phase 2 study of DDP733 in GERD patients in 2008.

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT3), which Dynogen is developing for gastrointestinal conditions such as GERD and irritable bowel syndrome with constipation (IBS-c). In this translational medicine study, healthy volunteers were given a high fat meal to induce gastroesophageal reflux. Reflux events were measured by intraesophageal impedance (the electrical resistance that provides insight into the height and duration of a reflux episode).

“With this second set of positive proof-of-concept data for DDP733, following closely on the heels of our positive Phase 2 data for DDP733 in irritable bowel syndrome with constipation, we’ve unlocked the potential of this compound as a treatment for two distinct and underserved GI disorders,” said Lee R. Brettman, M.D., Chief Executive Officer at Dynogen. “We estimate the peak sales for these indications to be in excess of a billion dollars each, reflecting the significant unmet medical need represented by these disorders. Dynogen has the opportunity to make a real difference in the quality of life of many patients suffering from these disorders.”

“We designed this study with the dual goals of obtaining an indication of efficacy and e
'"/>




Page: 1 2 3

Related medicine technology :

1. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
2. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
5. Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen DDP733 Reduces Reflux Phase GERD Study
(Date:10/22/2014)... LONDON , October 22, 2014 ... Amicus Therapeutics Inc. (NASDAQ: FOLD ), Progenics ... Inc. (NASDAQ: THLD ), Idera Pharmaceuticals Inc. ... (NASDAQ: MACK). Free research on these five companies can ... Tuesday, October 21, 2014, the NASDAQ Composite ended at ...
(Date:10/22/2014)... FRANCISCO , Oct. 22, 2014 Moms ... and health trackers for themselves and their kids, according ... 2014 Report: Health & Fitness Go Mobile for Moms, ... Insights Series. BabyCenter, the number 1 pregnancy and parenting ... found that 55 percent of moms surveyed say they ...
(Date:10/22/2014)... 22, 2014  CryoLife, Inc. (NYSE: CRY ... focused on cardiac and vascular surgery, announced today that ... Executive Officer, has been elected to the Company,s Board ... Steven G. Anderson , Executive Chairman of CryoLife, stated, "Since ... be an excellent leader who is well positioned to ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... ... to Sonitor’s Ultrasound RTLS Technology Platform strengthen further the technology’s position as the ... ... Sonitor Technologies, the world leader in ultrasound-based real time locating systems for hospitals ...
... ... ... , ... , , , ...
... patients who regularly received massages averaging 14 minutes or more ... over four weeks, according to results of a study reported ... Society. In the study, sponsored by the National Cancer ... program to provide massage to patients at home. The multi-ethnic ...
... The introduction of prostate-specific antigen (PSA) testing as a screening ... beginning of the 1990s drastically increased the detection of PCa. ... men with PCa. To assess the risk of suicide among ... study was carried out in Sweden. The results are published ...
... Copenhagen, led by postdoc Luke Holman of the Center for ... B , published on the 24 February 2010, that ant ... Often, an ant colony has more than one queen. Multiple ... increasing the chance the colony will survive the hazardous first ...
... ... wristbands market with line of ready-to-ship LaserBand® products that can be instantly priced and ... ... in providing a complete range of printed products and services, today announced the launch ...
Cached Medicine News:Health News:Sonitor Technologies Announces New Staff Tag and Battery Powered Ultrasound Receiver 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 3Health News:Family members reduce stress in advanced cancer patients with 14 minute massages 2Health News:Plotting and treachery in ant royal families 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 3
... INTERING Vascular Graft, the newest vascular graft ... a leader in vascular surgical products for ... by reducing kinking and compression problems ... new graft provides all of the benefits ...
... necessary in cruciate ligament reconstruction procedures frequently ... surface. This condition, if not rectified with ... replacement. The GORE SMOOTHER Crucial Tool is ... The tool functions as both a trial ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... neurophysiological monitoring system has been designed ... the needs of the ever changing ... collection and analyzing data from multiple ... EMG, EEG and multiple patients at ...
Medicine Products: